2023-07-05 09:41:27 ET
- Cassava Sciences ( NASDAQ: SAVA ) announced Wednesday that its lead candidate simufilam slowed cognitive decline by 38% compared to placebo in a small proof-of-concept study for patients with mild-to-moderate Alzheimer’s disease.
- The U.S.-based trial named the Cognition Maintenance Study ( CMS ) involved 57 participants who completed 12 months of oral simufilam treatment in an open-label phase and then received 100 mg of simufilam or placebo.
- According to its topline data at six months, those on simufilam experienced a 0.9-point decline in ADAS-Cog, a clinical measure to assess the extent of Alzheimer’s. Meanwhile, those on placebo witnessed a 1.5-point decline in ADAS-Cog.
- 5% or more subjects didn’t report treatment-emergent adverse events, and the study drug, at twice daily dosing, was safe and well tolerated, the company said.
- Cassava ( SAVA ) is advancing simufilam in two large global Phase 3 clinical studies for about 1,750 patients with mild-to-moderate Alzheimer’s disease. The company plans to complete enrollments for both trials by the end of 2023.
For further details see:
Cassava Sciences says Alzheimer’s therapy outperformed in small trial